Baird Downgrades Cogent (COGT) to Neutral, 'fairly valued around these levels'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Baird Downgrades Cogent (COGT) to Neutral, 'fairly valued around these levels'

Cogent (COGT) PT Raised to $13 at Citi

February 26, 2024 2:58 AM EST

Citi analyst David Lebowitz raised the price target on Cogent (NASDAQ: COGT) to $13.00 (from $11.00) while maintaining a Buy rating.... More

Cogent (COGT) PT Raised to $18 at Needham & Company

February 23, 2024 7:33 AM EST

Needham & Company analyst Ami Fadia raised the price target on Cogent (NASDAQ: COGT) to $18.00 (from $15.00) while maintaining a Buy rating.... More

Cogent Biosciences (COGT) Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

February 22, 2024 2:30 PM EST

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported positive Part 1b data from the Companys ongoing SUMMIT trial evaluating bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM) at the 2024 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) meeting taking place February 23-26, 2024 in Washington, D.C.

The... More